Alkermes PLC
ALKSHealthcare|Drug Manufacturers - Specialty & Generic|Ireland
$51.95
-1.82 (-3.39%)
DCF (FCF)
$20.11
Earnings Power
$12.19
Clinical Trials (115)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05028062 Naltrexone in AUD Reward Drinkers | Alcohol Use Disorder, Alcoholism | P4 | Recruiting | 60 | RCT, Double-blind | XR-NTX 380 mg, intramuscular injection, Placebo intramuscular injection |
| NCT07540897 A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | Narcolepsy Type 1 | P3 | Recruiting | 150 | RCT, Double-blind | ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo |
| NCT06767683 A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia | Narcolepsy Type 1, Narcolepsy Type 2 | P2P3 | Recruiting | 256 | Open-label | ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg, ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg |
| NCT05303064 Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder | Schizophrenia, Bipolar I Disorder | P3 | Recruiting | 220 | RCT, Double-blind | OLZ/SAM, Olanzapine |
| NCT07455383 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | Narcolepsy Type 1 | P3 | Recruiting | 150 | RCT, Double-blind | ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo |
| NCT07502443 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | Narcolepsy Type 2 | P3 | Recruiting | 176 | RCT, Double-blind | ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3, Placebo |
| NCT06843590 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | Idiopathic Hypersomnia | P2 | Recruiting | 126 | RCT, Double-blind | ALKS 2680, Placebo |
| NCT05495984 Neuroplasticity in Maternal Opioid Use Disorder (OUD) | Opioid Use Disorder | N/A | Recruiting | 15 | Open-label | — |
| NCT01246765 National Pregnancy Registry for Psychiatric Medications | Pregnant Women, Psychotropic Drugs | Recruiting | 5,000 | — | — | |
| NCT04203056 Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode | Schizophrenia, Schizoaffective Disorder, Depressive Type | P4 | Terminated | 15 | RCT, Open-label | Aripiprazole Lauroxil, ARI-ORAL, AL-NCD |
| NCT00620750 Extended-release Naltrexone for Alcohol Dependence in Primary Care | Alcohol Dependence | P4 | Completed | 72 | Open-label | Extended release injectable naltrexone (Vivitrol) |
| NCT05662306 C-Cog in Early Course Schizophrenia Study | Schizophrenia | P4 | Terminated | 1 | Open-label | Aripiprazole Lauroxil |
| NCT00511836 ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults | Alcohol Dependence | P4 | Completed | 31 | RCT, Double-blind | VIVITROL 380 mg, Placebo |
| NCT02634320 A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia | Schizophrenia | P4 | Completed | 51 | Open-label | Aripiprazole Lauroxil |
| NCT01563718 Pre-Release VIVITROL for Opioid Dependent Inmates | Substance-Related Disorders | P4 | Completed | 26 | RCT, Open-label | naltrexone for extended release injectable suspension |
| NCT01471145 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT | Opioid-Related Disorders, Heroin Dependence | P4 | Completed | 40 | Open-label | Naltrexone |
| NCT01453374 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration | Opioid Dependence | P4 | Completed | 27 | Open-label | VIVITROL 380mg |
| NCT02978417 Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings | Opioid-Related Disorders | P4 | Completed | 14 | RCT, Open-label | Naltrexone for extended-release injectable suspension, Oral naltrexone |
| NCT00355849 Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 555 | RCT, Open-label | Human Insulin Inhalation Powder, Insulin Glargine |
| NCT03345979 A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | Schizophrenia | P3 | Completed | 200 | RCT, Double-blind | Paliperidone Palmitate |
| NCT01218958 ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults | Alcoholism | P3 | Completed | 624 | RCT, Double-blind | Medisorb naltrexone 190 mg, Medisorb naltrexone 380 mg, Placebo matching Medisorb naltrexone 190 mg, Placebo matching Medisorb naltrexone 380 mg |
| NCT03201757 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | Schizophrenia, Schizophreniform Disorder | P3 | Completed | 523 | Open-label | ALKS 3831 |
| NCT02141399 A Long-Term Safety Study of ALKS 5461 | Major Depressive Disorder | P3 | Completed | 1,485 | Open-label | ALKS 5461 |
| NCT00391209 Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P3 | Completed | 379 | RCT, Open-label | simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder |
| NCT00447213 A Study for Patients With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1 | P2P3 | Completed | 70 | RCT, Open-label | Insulin glargine, Human Insulin Inhalation Powder, Injectable Insulin |
| NCT02873208 A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia | Schizophrenia | P3 | Completed | 266 | Open-label | ALKS 3831 |
| NCT02158546 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study | Major Depressive Disorder | P3 | Completed | 447 | RCT, Double-blind | ALKS 5461, Placebo |
| NCT00490854 A Study for Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P2P3 | Completed | 129 | RCT, Open-label | Human Insulin Inhalation Powder, Neutral protamine hagedorn insulin |
| NCT01218997 ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®) | Alcoholism | P3 | Completed | 436 | RCT, Open-label | Medisorb naltrexone 380 mg, Oral naltrexone 50 mg |
| NCT02158533 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study | Major Depressive Disorder | P3 | Completed | 385 | RCT, Double-blind | High Dose ALKS 5461, Low Dose ALKS 5461, Placebo |
| NCT02537574 Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) | Opioid Use Disorder | P3 | Completed | 380 | RCT, Double-blind | NTX/BUP, NTX/PBO-B, PBO-N/PBO-B |
| NCT00325364 Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 415 | RCT, Open-label | Human Insulin Inhalation Powder, Injectable insulin |
| NCT03187769 Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder | Schizophrenia, Schizophreniform Disorders | P3 | Completed | 426 | RCT, Double-blind | ALKS 3831, Olanzapine |
| NCT01895452 An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) | Schizophrenia | P3 | Completed | 291 | RCT, Double-blind | ALKS 9072, Low Dose, ALKS 9072, High Dose |
| NCT00356109 Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes | Diabetes Mellitus, Type 1 | P3 | Completed | 494 | RCT, Open-label | Human Insulin Inhalation Powder, Injectable insulin, Insulin Glargine |
| NCT02634307 A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 | Multiple Sclerosis | P3 | Completed | 1,057 | Open-label | ALKS 8700 |
| NCT01180647 Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail | Opiate Dependence | P3 | Completed | 48 | RCT, Open-label | Extended-Release Naltrexone |
| NCT02669758 A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia | Schizophrenia | P3 | Completed | 281 | Open-label | ALKS 3831 |
| NCT00834080 ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals | Opiate Dependence | P3 | Completed | 38 | Open-label | Medisorb naltrexone 380 mg |
| NCT00501631 ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence | Alcohol Dependence | P3 | Completed | 300 | RCT, Double-blind | VIVITROL 380 mg, Placebo for VIVITROL 380 mg |
| NCT00156923 ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults | Alcoholism | P3 | Completed | 108 | Open-label | Medisorb naltrexone 380 mg, Medisorb naltrexone 190 mg |
| NCT01436032 Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery | Laparoscopic Surgery | P3 | Terminated | 50 | RCT, Double-blind | N1539, N1539, N1539, Ketorolac Tromethamine, Placebo |
| NCT02218008 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study | Major Depressive Disorder | P3 | Completed | 407 | RCT, Double-blind | ALKS 5461, Placebo |
| NCT03610048 A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) | Refractory Major Depressive Disorder | P3 | Terminated | 175 | Open-label | ALKS 5461 |
| NCT00678418 ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence | Opiate Dependence | P3 | Completed | 250 | RCT, Double-blind | VIVITROL® 380 mg, Placebo |
| NCT04987229 Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects | Bipolar I Disorder, Schizophrenia | P3 | By Invite | 236 | Open-label | OLZ/SAM |
| NCT03188185 A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) | Major Depressive Disorder | P3 | Completed | 278 | RCT, Double-blind | ALKS 5461, ALKS 5461 Placebo |
| NCT02694328 A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) | Schizophrenia | P3 | Completed | 561 | RCT, Double-blind | ALKS 3831, Olanzapine |
| NCT01469039 A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia | Schizophrenia | P3 | Completed | 623 | RCT, Double-blind | ALKS 9072, Placebo |
| NCT03711318 Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals | Heroin Dependence | P3 | Terminated | 8 | Open-label | Buprenorphine/naloxone |
| NCT02110264 Injectable Pharmacotherapy for Opioid Use Disorders (IPOD) | Opioid Use Disorders | P3 | Completed | 151 | RCT, Open-label | XR-NTX |
| NCT03093324 A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 | Relapsing Remitting Multiple Sclerosis | P3 | Completed | 506 | RCT, Double-blind | ALKS 8700, Dimethyl Fumarate |
| NCT02085135 A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD) | Major Depressive Disorder | P3 | Completed | 66 | RCT, Double-blind | ALKS 5461 |
| NCT00437112 Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 142 | RCT, Open-label | Human Insulin Inhalation Powder, Insulin Glargine |
| NCT00127634 Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes | Diabetes Mellitus, Type 1 | P3 | Completed | 385 | RCT, Open-label | Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine |
| NCT01626456 A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) | Schizophrenia | P3 | Completed | 478 | RCT, Double-blind | ALKS 9072, Low, ALKS 9072, High |
| NCT01218971 ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®) | Alcohol Dependence | P3 | Completed | 332 | Double-blind | Medisorb naltrexone 190 mg, Medisorb naltrexone 380 mg |
| NCT02696434 Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL | Opioid Use Disorder | P3 | Completed | 101 | RCT, Double-blind | Naltrexone, Placebo, Buprenorphine |
| NCT02634346 A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) | Schizophrenia | P3 | Completed | 403 | RCT, Double-blind | ALK3831, Olanzapine, Placebo |
| NCT00157339 Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD | Diabetes Mellitus, Asthma | P3 | Completed | 299 | RCT, Open-label | Human Insulin Inhalation Powder, injected insulin |
| NCT00156936 ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997]) | Alcoholism, Opiate Dependence | P3 | Terminated | 108 | Open-label | Medisorb naltrexone 380 mg, Oral naltrexone to Medisorb naltrexone 380 mg |
| NCT01218984 ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids | Opiate Dependence | P2 | Completed | 27 | RCT, Double-blind | Medisorb naltrexone 75 mg, Medisorb naltrexone 150 mg, Medisorb naltrexone 300 mg, Hydromorphone (10 mg/mL), Naloxone Challenge and Oral Naltrexone Tolerability Testing |
| NCT00063128 Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus. | Diabetes Mellitus, Type 1 | P2 | Completed | 119 | RCT, Open-label | insulin, human insulin inhalation powder (HIIP) |
| NCT01690546 Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence | Opiate Dependence | P2 | Completed | 38 | Open-label | very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone |
| NCT06555783 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 | Narcolepsy Type 2 | P2 | Completed | 93 | RCT, Double-blind | ALKS 2680, Placebo |
| NCT01098435 ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder | Binge Eating Disorder | P2 | Completed | 69 | RCT, Double-blind | RDC-0313 (ALKS 33), Placebo |
| NCT01903837 A Study of ALKS 3831 in Adults With Schizophrenia | Schizophrenia | P2 | Completed | 347 | RCT, Double-blind | Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo, Olanzapine |
| NCT06358950 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) | Narcolepsy Type 1 | P2 | Completed | 92 | RCT, Double-blind | ALKS 2680, Placebo |
| NCT01100151 ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC) | Opioid-induced Constipation | P2 | Completed | 60 | RCT, Double-blind | RDC-1036 (ALKS 37), Placebo |
| NCT00801684 ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD | Chronic Obstructive Pulmonary Disease (COPD) | P2 | Completed | 24 | RCT, Double-blind | Placebo, TrIP-2D, TrIP-2SS, TrIP-2D, TrIP-2SS + Foradil |
| NCT00465959 Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | P1P2 | Completed | 24 | RCT, Double-blind | trospium chloride inhalation powder (TrIP), Placebo |
| NCT00777062 VIVITROL as a Treatment for Cocaine and Alcohol Dependence | Cocaine Dependence, Alcohol Dependence | P2 | Completed | 80 | RCT, Double-blind | VIVITROL (Naltrexone extended-release injectable suspension), Placebo |
| NCT00099515 Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP) | Diabetes Mellitus, Type 2 | P2 | Completed | 97 | RCT, Open-label | LY041001 (HIIP), LY041001 (HIIP) |
| NCT00981617 ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence | Alcohol Dependence | P2 | Completed | 406 | RCT, Double-blind | ALKS33 (RDC-0313) (1 mg), ALKS33 (RDC-0313) (2.5 mg), ALKS33 (RDC-0313) (10 mg), Placebo |
| NCT01418092 ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC) | OIC | P2 | Completed | 91 | RCT, Double-blind | ALKS 37, Placebo |
| NCT01449565 Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) | Amphetamine-Related Disorders | P2 | Completed | 100 | RCT, Double-blind | Naltrexone, Placebo |
| NCT01381107 ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD | Major Depressive Disorder | P1P2 | Completed | 32 | RCT, Double-blind | ALKS 5461, Placebo |
| NCT04576507 Repeated Cannabis Administration on Experimental Pain and Abuse Liability | Cannabis, Pain | P2 | Completed | 10 | Open-label | Active Cannabis, Placebo Cannabis |
| NCT01500200 A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) | Major Depressive Disorder | P2 | Completed | 142 | RCT, Double-blind | ALKS 5461, Placebo |
| NCT02161718 A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder | Schizophrenia, Alcohol Use Disorder | P2 | Completed | 300 | RCT, Double-blind | Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine |
| NCT01382797 ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC) | Opioid-induced Constipation | P2 | Completed | 157 | RCT, Double-blind | ALKS 37, Placebo |
| NCT01932801 Harm Reduction With Pharmacotherapy (HaRP) | Alcohol Use Disorder | P2 | Completed | 308 | RCT, Double-blind | XR-NTX |
| NCT01084161 Study to Evaluate the Efficacy, Safety and Tolerability of N1539 | Hysterectomy | P2 | Completed | 486 | RCT, Double-blind | N1539, N1539, N1539, N1539, placebo, Morphine, N1539 |
| NCT00945763 Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery | Dental Pain | P2 | Completed | 230 | RCT, Double-blind | N1539, placebo, N1539, N1539, Motrin |
| NCT02479308 A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers | Healthy | P1 | Completed | 129 | RCT, Double-blind | Moxifloxacin, ALKS 5461, Placebo |
| NCT03668314 Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects | Healthy | P1 | Completed | 84 | RCT, Double-blind | RDN-929, Placebo oral capsule, RDN-929 TBD dose, RDN-929, Placebo oral capsule |
| NCT01493726 A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia | Schizophrenia | P1 | Completed | 88 | RCT, Double-blind | ALKS 9072, Low dose, ALKS 9072, Med dose, ALKS 9072, High dose, Placebo |
| NCT02272764 A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers | Pharmacokinetics | P1 | Completed | 24 | RCT, Double-blind | Itraconazole, ALKS 5461 |
| NCT02504463 A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers | Healthy | P1 | Completed | 10 | Open-label | Samidorphan IV, [14c]-Samidorphan sublingual, [14c]-Samidorphan oral |
| NCT02508506 Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function | Renal Impairment | P1 | Completed | 22 | Open-label | ALKS 5461 |
| NCT02922426 An Insulin Sensitivity Study in Healthy Subjects | Healthy Volunteers | P1 | Completed | 60 | RCT, Double-blind | ALKS 3831, Olanzapine, Placebo |
| NCT01046539 Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults | Substance-Related Disorders | P1 | Completed | 12 | RCT, Double-blind | RDC-0313 + Buprenorphine, Placebo |
| NCT05019105 Phase 1 ALKS 1140 in Healthy Adults | Central Nervous System Diseases | P1 | Terminated | 20 | RCT, Double-blind | Placebo, ALKS 1140 |
| NCT04987658 Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder | Bipolar I Disorder | P1 | Completed | 7 | Open-label | OLZ/SAM |
| NCT00800319 ALK33-001: A Study of RDC-0313 Administered to Healthy Adults | Alcohol Dependence | P1 | Completed | 16 | RCT, Double-blind | RDC-0313, Placebo |
| NCT00802035 ALK29-002: A Study of Baclofen Formulations in Healthy Adults | Alcohol Dependence | P1 | Completed | 16 | Open-label | Baclofen IR, Baclofen ER |
| NCT02413281 A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users | Healthy | P1 | Completed | 56 | RCT, Double-blind | ALKS 5461, Buprenorphine, Placebo |
| NCT02804568 A Phase 1 Safety Study in Adults With Schizophrenia | Schizophrenia | P1 | Completed | 42 | RCT, Open-label | ALKS 3831 |
| NCT03963973 A 28 Day Parallel Group Study to Assess the Effects of RDN-929 | Healthy | P1 | Terminated | 7 | RCT, Double-blind | RDN-929 oral capsule, Placebo oral capsule |
| NCT00002316 The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis | Meningitis, Cryptococcal, HIV Infections | P1 | Completed | — | Double-blind | Lobradimil, Amphotericin B |
| NCT02521857 A Water Consumption Study of ALKS 5461 in Healthy Volunteers | Healthy | P1 | Completed | 30 | Open-label | ALKS 5461 |
| NCT02452801 Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function | Hepatic Impairment | P1 | Completed | 40 | Open-label | ALKS 5461 |
| NCT02545439 A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 24 | Open-label | ALKS 5461 |
| NCT01366001 ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine | Cocaine Abuse | P1 | Completed | 33 | RCT, Double-blind | ALKS 33-BUP, ALKS 33, Placebo |
| NCT05547100 Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan | Focus of Study is on Healthy Lactating Women | P1 | Completed | 12 | Open-label | LYBALVI |
| NCT02636842 A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder | Schizophrenia, Schizoaffective Disorder | P1 | Completed | 47 | Open-label | Aripiprazole Lauroxil |
| NCT02320032 An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia | Schizophrenia | P1 | Completed | 140 | RCT, Open-label | Aripiprazole Lauroxil |
| NCT02068105 A Study of ALKS 5461 in Healthy Volunteers | Pharmacokinetics | P1 | Completed | 104 | RCT, Double-blind | ALKS 5461, Placebo |
| NCT02218021 A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users | Healthy Volunteers | P1 | Completed | 59 | RCT, Double-blind | Samidorphan, Placebo, Oxycodone |
| NCT07680114 Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls | Schizophrenia | N/A | Not Yet Recruiting | 20 | RCT, Open-label | — |
| NCT04928703 Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers | Healthy | Early P1 | Completed | 33 | RCT, Double-blind | Ketamine |
| NCT04025502 Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects | Schizophrenia | Completed | 161 | — | — | |
| NCT03919994 Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS) | Schizophrenia | Completed | 338 | — | — | |
| NCT03577262 A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density | Healthy, Alzheimer Disease | Early P1 | Completed | 19 | Open-label | — |
| NCT01422837 ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry | Opioid Dependence | Completed | 403 | — | — |